AIMS: Radiation-associated angiosarcomas (RT-ASs) of the breast are rare tumours with a poor prognosis. MYC gene amplification is considered to be the hallmark of RT-AS, and is sometimes used as a diagnostic tool to distinguish it from other radiation-associated vascular lesions. However, a small subset of RT-ASs lacks MYC amplification, and this may be associated with better outcome. Loss of trimethylation at lysine 27 of histone 3 (H3K27me3) expression by immunohistochemistry (IHC) has been recently postulated as an additional diagnostic marker for RT-AS. The aims of this study were to evaluate the impact of MYC amplification as detected by fluorescence in-situ hybridisation and/or next-generation sequencing on clinicopathological features and outcome in a large cohort of RT-ASs, compare outcome with those of radiation-associated sarcomas (RT-Ss) of the breast other than angiosarcoma, and evaluate expression of H3K27me3 IHC in these groups. METHODS AND RESULTS: Eighty-one RT-ASs were identified, including 73 that were MYC-amplified and 8 (10%) that were MYC-non-amplified. MYC-amplified RT-ASs were diagnosed in older patients (median age, 69 years versus 61 years). The 5-year disease-specific survival and 5-year overall survival rates were 56% and 47%, respectively. Older age, larger tumour size, positive margin and MYC amplification were associated with worse prognosis. None of the RT-ASs showed complete loss of H3K27me3 IHC expression. All 18 RT-Ss were MYC-non-amplified, and complete loss of H3K27me3 expression was seen in 2 cases. We found no difference in prognosis between RT-AS and RT-S. CONCLUSIONS: RT-AS of the breast is associated with a poor prognosis. Older age at diagnosis, larger tumour size, positive margin at excision and MYC amplification are associated with worse prognosis.
AIMS: Radiation-associated angiosarcomas (RT-ASs) of the breast are rare tumours with a poor prognosis. MYC gene amplification is considered to be the hallmark of RT-AS, and is sometimes used as a diagnostic tool to distinguish it from other radiation-associated vascular lesions. However, a small subset of RT-ASs lacks MYC amplification, and this may be associated with better outcome. Loss of trimethylation at lysine 27 of histone 3 (H3K27me3) expression by immunohistochemistry (IHC) has been recently postulated as an additional diagnostic marker for RT-AS. The aims of this study were to evaluate the impact of MYC amplification as detected by fluorescence in-situ hybridisation and/or next-generation sequencing on clinicopathological features and outcome in a large cohort of RT-ASs, compare outcome with those of radiation-associated sarcomas (RT-Ss) of the breast other than angiosarcoma, and evaluate expression of H3K27me3 IHC in these groups. METHODS AND RESULTS: Eighty-one RT-ASs were identified, including 73 that were MYC-amplified and 8 (10%) that were MYC-non-amplified. MYC-amplified RT-ASs were diagnosed in older patients (median age, 69 years versus 61 years). The 5-year disease-specific survival and 5-year overall survival rates were 56% and 47%, respectively. Older age, larger tumour size, positive margin and MYC amplification were associated with worse prognosis. None of the RT-ASs showed complete loss of H3K27me3 IHC expression. All 18 RT-Ss were MYC-non-amplified, and complete loss of H3K27me3 expression was seen in 2 cases. We found no difference in prognosis between RT-AS and RT-S. CONCLUSIONS: RT-AS of the breast is associated with a poor prognosis. Older age at diagnosis, larger tumour size, positive margin at excision and MYC amplification are associated with worse prognosis.
Authors: Kristine M Cornejo; April Deng; Hong Wu; Ediz F Cosar; Ashraf Khan; Maryann St Cyr; Keith Tomaszewicz; Karen Dresser; Patrick O'Donnell; Lloyd Hutchinson Journal: Hum Pathol Date: 2015-03-10 Impact factor: 3.466
Authors: Christoph Käcker; Alexander Marx; Katharina Mössinger; Frederike Svehla; Ulrike Schneider; Pancras Cornelis Wilhelmus Hogendoorn; Ole Steen Nielsen; Stefan Küffer; Christian Sauer; Cyril Fisher; Christian Hallermann; Jörg Thomas Hartmann; Jean-Yves Blay; Gunhild Mechtersheimer; Peter Hohenberger; Philipp Ströbel Journal: Genes Chromosomes Cancer Date: 2012-09-25 Impact factor: 5.006
Authors: Tianhua Guo; Lei Zhang; Ning-En Chang; Samuel Singer; Robert G Maki; Cristina R Antonescu Journal: Genes Chromosomes Cancer Date: 2011-01 Impact factor: 5.006
Authors: Dara S Ross; Ahmet Zehir; Donavan T Cheng; Ryma Benayed; Khedoudja Nafa; Jaclyn F Hechtman; Yelena Y Janjigian; Britta Weigelt; Pedram Razavi; David M Hyman; José Baselga; Michael F Berger; Marc Ladanyi; Maria E Arcila Journal: J Mol Diagn Date: 2016-12-25 Impact factor: 5.568
Authors: Jeffrey K Mito; Devarati Mitra; Constance M Barysauskas; Adrián Mariño-Enriquez; Elizabeth A Morgan; Christopher D M Fletcher; Chandrajit P Raut; Elizabeth H Baldini; Leona A Doyle Journal: Int J Radiat Oncol Biol Phys Date: 2019-01-29 Impact factor: 7.038
Authors: Steven D Billings; Jesse K McKenney; Andrew L Folpe; Michael C Hardacre; Sharon W Weiss Journal: Am J Surg Pathol Date: 2004-06 Impact factor: 6.394
Authors: Evan Rosenbaum; Cristina R Antonescu; Shaleigh Smith; Martina Bradic; Daniel Kashani; Allison L Richards; Mark Donoghue; Ciara M Kelly; Benjamin Nacev; Jason E Chan; Ping Chi; Mark A Dickson; Mary L Keohan; Mrinal M Gounder; Sujana Movva; Viswatej Avutu; Katherine Thornton; Ahmet Zehir; Anita S Bowman; Samuel Singer; William Tap; Sandra D'Angelo Journal: J Immunother Cancer Date: 2022-04 Impact factor: 12.469